REGENXBIO Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by REGENXBIO Inc. (RGNX) on June 5, 2023, regarding events occurring on June 2, 2023. The filing details the results of the Company's Annual Meeting of Stockholders.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results and does not contain financial performance data.
Material Changes and Voting Results
The following proposals were voted upon at the Annual Meeting:
- Proposal 1 (Election of Directors): Three Class II directors were elected to serve until the 2026 annual meeting.
- Jean Bennett, M.D., Ph.D.: 30,318,877 votes for; 7,665,786 votes withheld.
- A.N. "Jerry" Karabelas, Ph.D.: 35,490,395 votes for; 2,494,268 votes withheld.
- Daniel Tassé: 35,984,653 votes for; 2,000,010 votes withheld.
- Proposal 2 (Ratification of Auditors): Stockholders ratified the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the year ending December 31, 2023.
- Votes For: 39,799,734
- Votes Against: 50,694
- Votes Abstaining: 92,000
- Proposal 3 (Executive Compensation): Stockholders approved, on an advisory basis, the compensation of the named executive officers.
- Votes For: 36,733,345
- Votes Against: 1,131,884
- Votes Abstaining: 111,321
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. Refer to the definitive proxy statement on Schedule 14A filed on April 6, 2023, for detailed information on proposals and executive compensation.
Key Facts for Investor Verification
- Verify the total number of shares entitled to vote at the Annual Meeting to contextualize the voting percentages.
- Review the Schedule 14A Proxy Statement filed on April 6, 2023, for details on the executive compensation package approved in Proposal 3.
- Confirm the tenure and specific responsibilities of the newly elected Class II directors.
- Note that this 8-K contains no financial performance updates; investors should refer to the most recent 10-Q or 10-K for financial metrics.